drugset / Trial / NCT05674175
Co-administration of CART22-65s and huCART19 for B-ALL
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia (B-ALL).
Timeline
- Start
- 2023-01-25
- Primary completion
- 2028-07-01
- Completion
- 2029-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CART22-65s | Cell therapy | — | — |
| Subject | huCART19 | Cell therapy | — | — |